| Literature DB >> 11412979 |
M R Michaelides1, J F Dellaria, J Gong, J H Holms, J J Bouska, J Stacey, C K Wada, H R Heyman, M L Curtin, Y Guo, C L Goodfellow, I B Elmore, D H Albert, T J Magoc, P A Marcotte, D W Morgan, S K Davidsen.
Abstract
A novel series of biaryl ether reverse hydroxamate MMP inhibitors has been developed. These compounds are potent MMP-2 inhibitors with limited activity against MMP-1. Select members of this series exhibit excellent pharmacokinetic properties with long elimination half-lives (7 h) and high oral bioavailability (100%).Entities:
Mesh：
Substances：
Year: 2001 PMID： 11412979 DOI： 10.1016/s0960-894x(01)00031-2
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823